Let's Talk Oligonucleotides!

e-Bulletin   |   May 2015  

Ligand Binding Assays (LBA) play a key role in assessing Toxicokinetics (TK), Pharmacokinetics (PK) and Immunogenicity profiles (in animal species and in humans), in a variety of biological matrices, including CSF, plasma, serum, and tissues. Drug candidates, such as Oligonucleotides, require robust bioanalytical assays with low sensitivity for their determination in increasingly complex biological matrices: brain tissue, spinal cord, colon, ocular, kidney, liver, and skin.

How we can help
We design assays customized to the biochemical features of your biotherapeutic needs, aligned with your biomarker monitoring requirements. Our experience extends to all of the complex biological matrices listed above, at all levels of drug development. Our LBA assays are performed using validated technology platforms that include Mesoscale Imager, BioTek Multimode plate readers and Luminex multiplexing. In addition, we use SQI antibody isotyping systems for our innovative approach to multiplexing.

You will benefit from our scientists’ 20 years of experience in the development of biological products, novel biological entities and biosimilar therapeutics.

Click here to request our poster

"An Ultrafiltration Assay for Assessing
the Extent of Whole Plasma Protein Binding
of Antisense Oligonucleotides in Human
and Various Species Plasma" 

being presented at the 2015 AAPS National Biotechnology Conference on June 8,
and let's talk Oligonucleotides!

Take a virtual tour of our lab!
For more information, please contact us:
450 973-6077 | 888 267-7449 | contact@algopharm.com
© All Rights Reserved, Algorithme Pharma inc., 2015